The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.375 (24.59%)
Spread: 0.20 (11.111%)
Open: 1.525
High: 1.90
Low: 1.90
Prev. Close: 1.525
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jun 2023 10:55

RNS Number : 3509B
Shield Therapeutics PLC
01 June 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

W. Health L.P. ("Inventages")

City and country of registered office (if applicable)

The Bahamas

4. Full name of shareholder(s) (if different from 3.) v

Name

CGWL Nominees Limited

City and country of registered office (if applicable)

London, UK

5. Date on which the threshold was crossed or reached vi:

16 March 2023 (prior to AOP loan conversion)

6. Date on which issuer notified (DD/MM/YYYY):

25 May 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

0%

0%

0%

0%

Position of previous notification (if

applicable)

9.56%

0

9.56%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

0

0

0%

0%

SUBTOTAL 8. A

0

0%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

Vevey, Switzerland

Date of completion

31 May 2023

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFBMLTMTIMMRJ
Date   Source Headline
13th Dec 20227:01 amRNSPlacing & Subscription to raise approx. US$18m
13th Dec 20227:00 amRNSCollaborative Sales Agreement signed with Viatris
31st Oct 20227:00 amRNSRepublic of Korea update
27th Oct 20227:00 amRNSShelf-life for Accrufer® extended to 48 months
24th Oct 20227:00 amRNSData presented at ACG Annual Scientific Meeting
30th Sep 20227:00 amRNSBlock Listing 6 Monthly Return
15th Sep 20221:52 pmEQSHardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building
14th Sep 20222:17 pmRNSHolding(s) in Company
8th Sep 20227:00 amRNSHalf-year Report
1st Sep 20222:20 pmRNSHolding(s) in Company
1st Sep 20227:00 amRNSLaunch of new corporate brand and website
31st Aug 20222:00 pmRNSTotal Voting Rights Update
31st Aug 202211:00 amRNSNotice of Interim Results
30th Aug 20229:30 amRNSHolding(s) in Company
12th Aug 202211:45 amEQSHardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous
9th Aug 20224:45 pmRNSGrant of share options
1st Aug 20227:00 amRNSCompletion of Loan Agreement & Partial Conversion
27th Jul 20224:20 pmRNSResults of 2022 General Meeting
27th Jul 20224:15 pmRNSResults of 2022 Annual General Meeting
26th Jul 20227:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US
14th Jul 20227:00 amRNSNew Drug Submission accepted by Health Canada
8th Jul 20227:00 amRNSNotice of General Meeting
30th Jun 20224:41 pmRNSSecond Price Monitoring Extn
30th Jun 20224:36 pmRNSPrice Monitoring Extension
30th Jun 20222:06 pmRNSSecond Price Monitoring Extn
30th Jun 20222:00 pmRNSPrice Monitoring Extension
30th Jun 202211:05 amRNSSecond Price Monitoring Extn
30th Jun 202211:00 amRNSPrice Monitoring Extension
30th Jun 20229:05 amRNSSecond Price Monitoring Extn
30th Jun 20229:00 amRNSPrice Monitoring Extension
30th Jun 20227:01 amRNS2021 Annual Report and 2022 AGM Notice
30th Jun 20227:00 amRNSBusiness Update, Final Results&Financing Agreement
29th Jun 20227:00 amRNSNotice of Results
28th Jun 20224:40 pmRNSSecond Price Monitoring Extn
28th Jun 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20222:05 pmRNSSecond Price Monitoring Extn
28th Jun 20222:00 pmRNSPrice Monitoring Extension
29th Apr 20227:00 amRNSTotal Voting Rights Update
31st Mar 20223:50 pmRNSBlock Listing Application
31st Mar 20223:50 pmRNSBlock Listing 6 Monthly Return
21st Mar 20227:00 amRNSKYE Pharmaceuticals Files Accrufer® NDS in Canada
2nd Mar 20221:30 pmEQSHardman & Co Research: Shield Therapeutics (STX) - PBMs have bought in to Accrufer
25th Feb 20227:00 amRNSInvestor Presentation
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
23rd Feb 202211:05 amRNSSecond Price Monitoring Extn
23rd Feb 202211:00 amRNSPrice Monitoring Extension
18th Feb 20222:06 pmRNSSecond Price Monitoring Extn
18th Feb 20222:00 pmRNSPrice Monitoring Extension
17th Feb 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.